Impact of Dapagliflozin on Left Ventricular Diastolic Function of Patients with Type 2 Diabetic Mellitus with Chronic Heart Failure

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2018 Oct 10

PMID 30296931

Citations 79

Authors

Fumitaka Soga

Hidekazu Tanaka

Kazuhiro Tatsumi

Yasuhide Mochizuki

Hiroyuki Sano

Hiromi Toki

Kensuke Matsumoto

Junya Shite

Hideyuki Takaoka

Tomofumi Doi

Ken-Ichi Hirata

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to investigate the impact of sodium glucose cotransporter type 2 (SGLT2) inhibitors on left ventricular (LV) diastolic function of type 2 diabetes mellitus (T2DM) patients with heart failure (HF).

Methods: This trial was a prospective multicenter study of 58 T2DM patients with stable HF at five institutions in Japan. Patients who had been taking at least one antidiabetic drugs other than SGLT2 inhibitors started the administration of 5 mg/day of dapagliflozin. The physical examinations, blood tests, and echocardiography were performed at baseline and 6 months after administration of dapagliflozin. The primary endpoint was defined as a change in mitral inflow E and mitral e' annular velocities (E/e') between baseline and 6 months after the administration of dapagliflozin. The secondary end points consisted of a change in brain natriuretic peptide (BNP), LV mass index (LVMI) and left atrial volume index (LAVI).

Results: E/e' significantly decreased from 9.3 to 8.5 cm/s (p = 0.020) 6 months after administration of dapagliflozin. LAVI and LVMI significantly decreased from 31 to 26 mL/m (p = 0.001), and from 75.0 to 67.0 g/m (p < 0.001), respectively, 6 months after administration of dapagliflozin. No significant change was observed in BNP (from 27.9 to 28.9 pg/mL; p = 0.132) 6 months after administration of dapagliflozin, except for a significant decrease from 168.8 to 114.3 pg/mL (p = 0.012) in patients with BNP ≥ 100 pg/mL.

Conclusion: This prospective multicenter trial showed the beneficial effect of SGLT2 inhibitors on LV diastolic functional parameters for T2DM patients with HF. Our findings may thus offer a new insight into the management of T2DM patients. Trial registration UMIN000019789, Registered 28 September 2014, Date of registration: 11/14/2015, Date of enrolment of the first participant to the trial: 6/15/2016, Date of enrolment of the last participant to the trial: 12/9/2017.

Citing Articles

Effect of Dapagliflozin on Ventricular Arrhythmic Events in Heart Failure Patients With an Implantable Cardioverter Defibrillator.

De Masi De Luca G, Palama Z, Longo S, Barba F, Robles A, Nesti M Cardiol Res. 2025; 16(2):140-152.

PMID: 40051671 PMC: 11882230. DOI: 10.14740/cr2018.

The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.

Loria F, Mone P, Rispoli A, Di Fonzo R, Masarone D, Mancusi C Cardiovasc Diabetol. 2024; 23(1):423.

PMID: 39578847 PMC: 11583416. DOI: 10.1186/s12933-024-02515-5.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases.

Pham L, Mangmool S, Parichatikanond W ACS Pharmacol Transl Sci. 2024; 7(11):3279-3298.

PMID: 39539254 PMC: 11555527. DOI: 10.1021/acsptsci.4c00240.

Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials.

Gupta R, Umeh C, Mohta T, Vaidya A, Wolfson A, Nattiv J Int J Cardiol Heart Vasc. 2024; 55:101539.

PMID: 39502337 PMC: 11535350. DOI: 10.1016/j.ijcha.2024.101539.

The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis.

Sinha T, Gul U, Babar N, Israr F, Butt A, Chaudhari S Cureus. 2024; 16(9):e69711.

PMID: 39429324 PMC: 11490073. DOI: 10.7759/cureus.69711.

References

Boyer J, Thanigaraj S, Schechtman K, Perez J . Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004; 93(7):870-5. DOI: 10.1016/j.amjcard.2003.12.026. View

Paulus W, van Ballegoij J . Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 2010; 55(6):526-37. DOI: 10.1016/j.jacc.2009.06.067. View

Boulton A, Gries F, Jervell J . Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998; 15(6):508-14. DOI: 10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L. View

Haring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. PMC: 3816918. DOI: 10.2337/dc12-2673. View

Iribarren C, Karter A, Go A, Ferrara A, Liu J, Sidney S . Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22):2668-73. DOI: 10.1161/01.cir.103.22.2668. View

Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K . Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018; 17(1):73. PMC: 5963148. DOI: 10.1186/s12933-018-0717-9. View

Fang Z, Prins J, Marwick T . Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004; 25(4):543-67. DOI: 10.1210/er.2003-0012. View

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle H . Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014; 37(7):1815-23. DOI: 10.2337/dc13-3055. View

10.

Kim S, Lee Y, Lee S, Kang E, Cha B, Lee B . The renal tubular damage marker urinary N-acetyl-β-D-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2017; 16(1):16. PMC: 5267389. DOI: 10.1186/s12933-017-0497-7. View

11.

Holland D, Kumbhani D, Ahmed S, Marwick T . Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 2011; 57(16):1676-86. DOI: 10.1016/j.jacc.2010.10.057. View

12.

Devereux R, Alonso D, Lutas E, Gottlieb G, Campo E, Sachs I . Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57(6):450-8. DOI: 10.1016/0002-9149(86)90771-x. View

13.

Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S . Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016; 15(1):157. PMC: 5106779. DOI: 10.1186/s12933-016-0473-7. View

14.

Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L . Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017; 16(1):138. PMC: 5654086. DOI: 10.1186/s12933-017-0621-8. View

15.

Solomon S, Claggett B, Lewis E, Desai A, Anand I, Sweitzer N . Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2015; 37(5):455-62. PMC: 4751235. DOI: 10.1093/eurheartj/ehv464. View

16.

Marsenic O . Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009; 53(5):875-83. DOI: 10.1053/j.ajkd.2008.12.031. View

17.

Anand I, Rector T, Cleland J, Kuskowski M, McKelvie R, Persson H . Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011; 4(5):569-77. DOI: 10.1161/CIRCHEARTFAILURE.111.962654. View

18.

Hernandez A, Hammill B, OConnor C, Schulman K, Curtis L, Fonarow G . Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009; 53(2):184-92. PMC: 3513266. DOI: 10.1016/j.jacc.2008.09.031. View

19.

Daimon M, Akaishi M, Asanuma T, Hashimoto S, Izumi C, Iwanaga S . Guideline from Japanese Society of Echocardiography: 2018 focused update incorporated into Guidance for the Management and Maintenance of Echocardiography Equipment. J Echocardiogr. 2018; 16(1):1-5. PMC: 5818545. DOI: 10.1007/s12574-018-0370-z. View

20.

Verma S, Garg A, Yan A, Gupta A, Al-Omran M, Sabongui A . Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. Diabetes Care. 2016; 39(12):e212-e213. DOI: 10.2337/dc16-1312. View